CL2012003643A1 - Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension. - Google Patents

Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.

Info

Publication number: CL2012003643A1
Authority: CL; Chile
Prior art keywords: compound; dyslipidemia; glucagon; hypertension; treat
Prior art date: 2010-06-23

Application number

CL2012003643A

Other languages

English (en)

Inventor

Marie Skovgaard

Ditte Riber

Eddi Meier

Jens Rosengren Daugaard

Original Assignee

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-23

Filing date

2012-12-21

Publication date

2013-08-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44630045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-12-21 Application filed by Zealand Pharma As filed Critical Zealand Pharma As

2013-08-02 Publication of CL2012003643A1 publication Critical patent/CL2012003643A1/es

Links

150000001875 compounds Chemical class 0.000 title 3
208000032928 Dyslipidaemia Diseases 0.000 title 1
102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
206010020772 Hypertension Diseases 0.000 title 1
208000017170 Lipid metabolism disease Diseases 0.000 title 1
208000008589 Obesity Diseases 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Obesity (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2012003643A 2010-06-23 2012-12-21 Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension. CL2012003643A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA201000550		2010-06-23
US35862310P	2010-06-25	2010-06-25

Publications (1)

Publication Number	Publication Date
CL2012003643A1 true CL2012003643A1 (es)	2013-08-02

Family

ID=44630045

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012003643A CL2012003643A1 (es)	2010-06-23	2012-12-21	Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.

Country Status (23)

Country	Link
US (2)	US9403894B2 (es)
EP (1)	EP2585481B1 (es)
JP (1)	JP5937582B2 (es)
KR (1)	KR20130086339A (es)
CN (1)	CN103038250A (es)
AP (1)	AP3286A (es)
AR (1)	AR081975A1 (es)
AU (1)	AU2011269427A1 (es)
BR (1)	BR112012033227A2 (es)
CA (1)	CA2802889A1 (es)
CL (1)	CL2012003643A1 (es)
CO (1)	CO6660484A2 (es)
EA (1)	EA201291233A1 (es)
EC (1)	ECSP12012351A (es)
MX (1)	MX2012014774A (es)
NZ (1)	NZ604033A (es)
PE (1)	PE20130326A1 (es)
PH (1)	PH12012502461A1 (es)
SG (1)	SG186276A1 (es)
TN (1)	TN2012000567A1 (es)
TW (1)	TW201202265A (es)
UY (1)	UY33462A (es)
WO (1)	WO2011160630A2 (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602006020123D1 (de)	2005-05-04	2011-03-31	Zealand Pharma As	Glucagon-like-peptide-2- (glp-2-) analoga
AU2007319066B2 (en)	2006-11-08	2013-09-19	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (GLP-2) analogues
US8642540B2 (en)	2008-12-15	2014-02-04	Zealand Pharma A/S	Glucagon analogues
AU2008365557A1 (en)	2008-12-15	2011-07-21	Zealand Pharma A/S	Glucagon analogues
MA32970B1 (fr)	2008-12-15	2012-01-02	Zealand Pharma As	Analogues du glucagon
ES2502218T3 (es)	2008-12-15	2014-10-03	Zealand Pharma A/S	Análogos de glucagón
JP6054742B2 (ja)	2009-07-13	2016-12-27	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
CA2802897A1 (en)	2010-06-24	2011-12-29	Zealand Pharma A/S	Glucagon analogues
EA201390796A1 (ru) *	2011-01-20	2014-07-30	Зилэнд Фарма А/С	Применение ацилированного аналога глюкагона
MX354705B (es)	2011-09-23	2018-03-16	Novo Nordisk As	Analogos de glucagon novedosos.
KR20140114845A (ko) *	2011-12-23	2014-09-29	질랜드 파마 에이/에스	글루카곤 유사체
EA028929B1 (ru)	2012-05-03	2018-01-31	Зилэнд Фарма А/С	Аналоги глюкагоноподобного пептида-2 (glp-2)
CA2872314C (en)	2012-05-03	2021-08-31	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
JP2015525226A (ja)	2012-06-14	2015-09-03	サノフイ	エキセンディン−４ペプチドアナログ
NZ704043A (en)	2012-07-23	2017-07-28	Zealand Pharma As	Glucagon analogues
US9546205B2 (en)	2012-09-17	2017-01-17	Imperial Innovations Limited	Peptide analogues of glucagon and GLP1
GB2505941A (en) *	2012-09-17	2014-03-19	Imp Innovations Ltd	Peptide analogues of glucagon for the treatment of obesity and diabetes
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en)	2012-12-21	2018-05-28	Sanofi Sa	Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
US10450343B2 (en)	2013-03-21	2019-10-22	Sanofi-Aventis Deutschland Gmbh	Synthesis of cyclic imide containing peptide products
HUE034308T2 (en)	2013-03-21	2018-02-28	Sanofi Aventis Deutschland	Preparation of hydantoin-containing peptide products
AR095986A1 (es)	2013-04-03	2015-11-25	Sanofi Sa	Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
BR112015025464A2 (pt)	2013-04-18	2017-10-10	Novo Nordisk As	coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
AR098065A1 (es)	2013-10-17	2016-04-27	Zealand Pharma As	Análogos de glucagón acilados
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
AU2014345570B2 (en)	2013-11-06	2019-01-24	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
CA2929459C (en)	2013-11-06	2022-05-03	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086731A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
JP2017525656A (ja)	2014-06-04	2017-09-07	ノヴォノルディスクアー／エス	医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
EP3212218B1 (en)	2014-10-29	2021-06-30	Zealand Pharma A/S	Gip agonist compounds and methods
UA121874C2 (uk)	2015-02-17	2020-08-10	Елі Ліллі Енд Компані	Порошкова назальна композиція для лікування гіпоглікемії
AR103954A1 (es)	2015-03-18	2017-06-14	Zealand Pharma As	Análogos de amilina
WO2016168388A2 (en)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Therapies for obesity, diabetes and related indications
PL3283507T3 (pl)	2015-04-16	2020-05-18	Zealand Pharma A/S	Acylowany analog glukagonu
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
GB2566228A (en)	2016-06-09	2019-03-06	AmideBio LLC	Glucagon analogs and methods of use thereof
AU2017307033B2 (en)	2016-08-05	2020-11-26	Boehringer Ingelheim International Gmbh	Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors
AR109514A1 (es)	2016-09-09	2018-12-19	Zealand Pharma As	Análogos de amilina
KR101887577B1 (ko)	2016-10-19	2018-09-10	(주)케어젠	항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
AR110299A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
KR102502040B1 (ko)	2016-12-09	2023-02-24	질랜드 파마 에이/에스	아실화 glp-1/glp-2 이중 효능제
IL271245B2 (en)	2017-06-16	2023-10-01	Zealand Pharma As	Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
ES2973986T3 (es) *	2017-08-16	2024-06-25	Dong A St Co Ltd	Análogo peptídico acilado de oxintomodulina
CA3087925A1 (en)	2018-02-02	2019-08-08	Boehringer Ingelheim International Gmbh	Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
MX2020008053A (es)	2018-02-02	2020-09-07	Boehringer Ingelheim Int	Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat).
CN111655699B (zh)	2018-02-02	2023-07-14	勃林格殷格翰国际有限公司	用作饥饿素o-酰基转移酶(goat)抑制剂的杂环基取代的噁二唑并吡啶衍生物
JP7225253B2 (ja)	2018-02-02	2023-02-20	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体
SG11202010016QA (en)	2018-04-10	2020-11-27	Sanofi Aventis Deutschland	Lixisenatide synthesis with capping
MX2020010716A (es) *	2018-04-10	2021-03-09	Sanofi Aventis Deutschland	Metodo para escindir de la fase solida peptidos unidos a una fase solida.
US20220153853A1 (en)	2018-12-21	2022-05-19	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific protein
TWI771669B (zh)	2019-04-26	2022-07-21	美商美國禮來大藥廠	製備穩定胜肽調配物之方法
WO2021029698A1 (ko) *	2019-08-13	2021-02-18	애니젠 주식회사	엑세나타이드 유사체 및 이의 용도
KR20220100925A (ko)	2019-11-11	2022-07-18	베링거 인겔하임 인터내셔날 게엠베하	Npy2 수용체 작용제
EP4153599B1 (en)	2020-05-22	2024-03-13	Boehringer Ingelheim International GmbH	Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
WO2021233884A1 (en)	2020-05-22	2021-11-25	Boehringer Ingelheim International Gmbh	Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
CN113292646B (zh) *	2020-05-29	2022-05-13	东莞云璟生物技术有限公司	Glp-1/胰高血糖素双重激动剂融合蛋白
WO2022029231A1 (en)	2020-08-07	2022-02-10	Boehringer Ingelheim International Gmbh	Soluble npy2 receptor agonists
IL312600B2 (en)	2022-05-30	2025-12-01	Zealand Pharma As	Liquid formulations of amylin analogs
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
EP4686757A1 (en)	2024-07-31	2026-02-04	e-therapeutics PLC	Inhibitors of expression and/or function
AU2024408289A1 (en)	2023-12-22	2026-08-06	Tangram Therapeutics Plc	Inhibitors of expression and/or function
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ202757A (en)	1981-12-23	1985-11-08	Novo Industri As	Peptides and medicaments
DE122009000079I2 (de)	1996-08-30	2011-06-16	Novo Nordisk As Novo Alle	Glp-1 derivate
CZ295838B6 (cs)	1996-09-09	2005-11-16	Zealand Pharma A/S	Způsob výroby peptidů
EP0932614A1 (en)	1996-09-09	1999-08-04	Zealand Pharmaceuticals A/S	Peptide prodrugs containing an alpha-hydroxyacid linker
NZ504258A (en)	1997-11-14	2002-12-20	Amylin Pharmaceuticals Inc	Exendin 3 and 4 agonist compounds for the treatment of diabetes
AU757658B2 (en)	1998-03-09	2003-02-27	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1137667B1 (en)	1998-12-07	2004-11-17	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Analogues of glp-1
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
CA2361830A1 (en)	1999-03-17	2000-09-21	Novo Nordisk A/S	Method for acylating peptides and novel acylating agents
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
WO2003053460A1 (en)	2001-12-19	2003-07-03	Eli Lilly And Company	Crystalline compositions for controlling blood glucose
AU2002346490A1 (en)	2001-12-20	2003-07-09	Eli Lilly And Company	Insulin molecule having protracted time action
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
WO2004096854A2 (en)	2003-04-29	2004-11-11	Eli Lilly And Company	Insulin analogs having protracted time action
EP1891105B1 (en)	2005-06-13	2012-04-11	Imperial Innovations Limited	Oxyntomodulin analogues and their effects on feeding behaviour
US20090202497A1 (en)	2005-08-23	2009-08-13	The General Hospital Corporation	Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
CA2913805A1 (en)	2005-11-07	2007-05-18	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
US8343914B2 (en)	2006-01-06	2013-01-01	Case Western Reserve University	Fibrillation resistant proteins
EP2471810A1 (en)	2006-02-22	2012-07-04	Merck Sharp & Dohme Corporation	Oxyntomodulin derivatives
ZA200900545B (en)	2006-07-18	2010-03-31	Sanofi Aventis	Antagonist antibody against EPHA2 for the treatment of cancer
EP2074140B8 (en)	2006-10-04	2015-10-28	Case Western Reserve University	Fibrillation-resistant insulin and insulin analogues
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
NZ578948A (en)	2007-02-15	2012-03-30	Univ Indiana Res & Tech Corp	Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en) *	2007-06-15	2008-12-18	Zealand Pharma A/S	Glucagon analogues
EP2025684A1 (en)	2007-08-15	2009-02-18	Zealand Pharma A/S	Glucagon analogues
CA2703830A1 (en)	2007-11-20	2009-05-28	Ambrx, Inc.	Modified insulin polypeptides and their uses
DE102008003568A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111683A (ko)	2008-01-09	2010-10-15	사노피-아벤티스 도이칠란트 게엠베하	극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
DE102008003566A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
RU2524423C2 (ru)	2008-01-09	2014-07-27	Санофи-Авентис Дойчланд Гмбх	Новые производные инсулина с чрезвычайно замедленным профилем время/действие
WO2009129250A2 (en)	2008-04-14	2009-10-22	Case Western Reserve University	Meal-time insulin analogues of enhanced stability
AU2009240636A1 (en)	2008-04-22	2009-10-29	Case Western Reserve University	Isoform-specific insulin analogues
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
TWI541023B (zh)	2008-06-17	2016-07-11	印第安納大學科技研究公司	在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
CA2728284C (en)	2008-06-17	2019-09-10	Richard D. Dimarchi	Glucagon/glp-1 receptor co-agonists
PL219335B1 (pl)	2008-07-04	2015-04-30	Inst Biotechnologii I Antybiotyków	Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
EP2318432B1 (en)	2008-07-31	2015-09-02	Case Western Reserve University	Halogen-stabilized insulin
AU2008365557A1 (en)	2008-12-15	2011-07-21	Zealand Pharma A/S	Glucagon analogues
ES2502218T3 (es) *	2008-12-15	2014-10-03	Zealand Pharma A/S	Análogos de glucagón
MA32970B1 (fr) *	2008-12-15	2012-01-02	Zealand Pharma As	Analogues du glucagon
US8642540B2 (en)	2008-12-15	2014-02-04	Zealand Pharma A/S	Glucagon analogues
JP5789515B2 (ja)	2008-12-19	2015-10-07	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	インスリン類似体
US8697632B2 (en)	2008-12-19	2014-04-15	Indiana University Research And Technology Corporation	Amide based insulin prodrugs
CN101519446A (zh)	2009-03-31	2009-09-02	上海一就生物医药有限公司	一种重组人胰岛素及其类似物的制备方法
JP6054742B2 (ja)	2009-07-13	2016-12-27	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体
WO2011088837A1 (en) *	2010-01-20	2011-07-28	Zealand Pharma A/S	Treatment of cardiac conditions
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
CA2802897A1 (en)	2010-06-24	2011-12-29	Zealand Pharma A/S	Glucagon analogues
EA201390796A1 (ru)	2011-01-20	2014-07-30	Зилэнд Фарма А/С	Применение ацилированного аналога глюкагона
KR20140114845A (ko)	2011-12-23	2014-09-29	질랜드 파마 에이/에스	글루카곤 유사체
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
AR098065A1 (es)	2013-10-17	2016-04-27	Zealand Pharma As	Análogos de glucagón acilados
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues

2011
- 2011-06-22 AR ARP110102166A patent/AR081975A1/es unknown
- 2011-06-22 UY UY0001033462A patent/UY33462A/es not_active Application Discontinuation
- 2011-06-23 PH PH1/2012/502461A patent/PH12012502461A1/en unknown
- 2011-06-23 JP JP2013515697A patent/JP5937582B2/ja not_active Expired - Fee Related
- 2011-06-23 NZ NZ604033A patent/NZ604033A/en not_active IP Right Cessation
- 2011-06-23 KR KR1020137000529A patent/KR20130086339A/ko not_active Withdrawn
- 2011-06-23 AP AP2013006669A patent/AP3286A/xx active
- 2011-06-23 EP EP11741513.3A patent/EP2585481B1/en active Active
- 2011-06-23 EA EA201291233A patent/EA201291233A1/ru unknown
- 2011-06-23 CA CA2802889A patent/CA2802889A1/en not_active Abandoned
- 2011-06-23 PE PE2012002434A patent/PE20130326A1/es not_active Application Discontinuation
- 2011-06-23 US US13/702,841 patent/US9403894B2/en not_active Expired - Fee Related
- 2011-06-23 MX MX2012014774A patent/MX2012014774A/es not_active Application Discontinuation
- 2011-06-23 WO PCT/DK2011/000067 patent/WO2011160630A2/en not_active Ceased
- 2011-06-23 SG SG2012090890A patent/SG186276A1/en unknown
- 2011-06-23 CN CN2011800305150A patent/CN103038250A/zh active Pending
- 2011-06-23 AU AU2011269427A patent/AU2011269427A1/en not_active Abandoned
- 2011-06-23 TW TW100122081A patent/TW201202265A/zh unknown
- 2011-06-23 BR BR112012033227A patent/BR112012033227A2/pt not_active IP Right Cessation
2012
- 2012-11-30 TN TNP2012000567A patent/TN2012000567A1/en unknown
- 2012-12-20 EC ECSP12012351 patent/ECSP12012351A/es unknown
- 2012-12-21 CO CO12232550A patent/CO6660484A2/es unknown
- 2012-12-21 CL CL2012003643A patent/CL2012003643A1/es unknown
2016
- 2016-06-27 US US15/194,025 patent/US20160304576A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SG186276A1 (en)	2013-01-30
KR20130086339A (ko)	2013-08-01
BR112012033227A2 (pt)	2017-06-20
US20130157935A1 (en)	2013-06-20
CA2802889A1 (en)	2011-12-29
WO2011160630A3 (en)	2012-02-16
ECSP12012351A (es)	2013-01-31
US9403894B2 (en)	2016-08-02
MX2012014774A (es)	2013-01-29
AR081975A1 (es)	2012-10-31
NZ604033A (en)	2014-12-24
TW201202265A (en)	2012-01-16
PH12012502461A1 (en)	2013-02-18
TN2012000567A1 (en)	2014-04-01
EA201291233A1 (ru)	2013-07-30
CO6660484A2 (es)	2013-04-30
WO2011160630A2 (en)	2011-12-29
PE20130326A1 (es)	2013-03-17
AP3286A (en)	2015-05-31
EP2585481A2 (en)	2013-05-01
JP5937582B2 (ja)	2016-06-22
AP2013006669A0 (en)	2013-01-31
AU2011269427A1 (en)	2012-12-20
EP2585481B1 (en)	2015-08-19
UY33462A (es)	2012-01-31
CN103038250A (zh)	2013-04-10
JP2013534919A (ja)	2013-09-09
US20160304576A1 (en)	2016-10-20

Publication	Publication Date	Title
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2011001299A1 (es)	2012-01-13	Compuestos derivados de benzotiazoles; composicion farmaceutica; y su uso como inhibidores de raf para el tratamiento o profilaxis del cancer.
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
CL2011002877A1 (es)	2012-05-25	Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2012003415A1 (es)	2013-08-09	Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2015001207A1 (es)	2015-07-03	Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas, que comprende un análogo de oxintomodulina; y uso de la composición.
CL2012002606A1 (es)	2013-10-18	Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2014000801A1 (es)	2014-09-12	Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
CL2014001858A1 (es)	2014-09-26	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2013001338A1 (es)	2014-03-28	Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BR112014031262A2 (pt)	2017-06-27	composições biocatalisadoras inovadoras e processos para uso.
CL2012000772A1 (es)	2012-08-24	Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
BR112012016398A2 (pt)	2018-08-21	Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
CL2013000801A1 (es)	2013-11-29	Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
GT201400147A (es)	2015-04-06	Pirimidinas y triazinas fusionadas sustituidas y su uso
CL2008000793A1 (es)	2008-05-30	Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
BR112013006016A2 (pt)	2016-06-07	compostos de azabenzotiazol, composições e métodos de uso
CL2014002348A1 (es)	2015-01-23	Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
CL2014003339A1 (es)	2015-04-10	Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
CL2014003525A1 (es)	2015-04-10	Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CL2012003322A1 (es)	2014-03-28	Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
BRPI1009781A2 (pt)	2016-03-08	compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
CL2015001202A1 (es)	2015-07-03	Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2013001324A1 (es)	2014-05-16	Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.